Achieve Life Sciences Reports 74-80% Median Reduction In Smoking In Study

Achieve Life Sciences Inc ACHV a company focused on nicotine addiction, announced positive results Tuesday from the ORCA-1 dose-selection trial of cytisinicline for smoking cessation.

The primary endpoint was the reduction in daily smoking, a self-reported measure.

Across all treatment arms, subjects on cytisinicline experienced a 74-80-percent median reduction in the number of cigarettes smoked over a 25-day treatment period — compared to a 62-percent reduction in the placebo arms. 

Achieve Life Sciences shares were trading down by 5.67 percent to $3.42 after the open Tuesday. 

Related Links:

Slack's IPO: What You Need To Know

7 Stocks To Watch For June 11, 2019